Key result
Panax ginseng extract and ginsenosides reduce intracellular cholesterol in vitro via SREBP-2 and LXR-IDOL pathways.
Why the study?
Hypercholesterolemia contributes to atherosclerosis and cardiovascular risk, but the effects of Panax ginseng and its ginsenosides on cholesterol homeostasis were not fully understood.
Answers are grounded in this paper and cite their sources.
Panax ginseng extract and ginsenosides Rb1 and Rb2 reduce intracellular cholesterol levels in vitro through modulation of multiple lipid metabolism pathways, including statin-like inhibition of HMGCR.
Hypercholesterolemia is harmful for human health since it may favor atherosclerosis and increase the risk of cardiovascular disease. To investigate the effect of a Panax ginseng extract and of some major components thereof (namely, ginsenosides Rb1 and Rb2) on cholesterol homeostasis in vitro, we quantitated total and free cholesterol levels and monitored the changes in the levels of key mediators of cholesterol synthesis, efflux and clearance. Treatments with ginsenosides and the extract reduced intracellular cholesterol levels by modulating the SREBP-2-HMGCR and LXR-IDOL signaling pathways. In addition, we observed an upregulation of the expression of the membrane transporters ABCA1 and ABCG1 and of cholesterol 7-hydroxylase suggesting the stimulation of processes for cholesterol excretion and cholesterol conversion into bile acids. Furthermore, both ginsenosides targeted HMGCR and inhibited its activity via a statin-like mechanism. Globally, our findings aid in deciphering the mechanisms of action activated by a major class of ginseng components in regulating lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Cecarini et al. (2023) studied Hypercholesterolemia. Panax ginseng extract and ginsenosides Rb1 and Rb2 was evaluated on Intracellular cholesterol levels and key mediators of cholesterol synthesis, efflux, and clearance. Panax ginseng extract and ginsenosides Rb1 and Rb2 reduced intracellular cholesterol levels in vitro by modulating SREBP-2-HMGCR and LXR-IDOL signaling pathways and inhibiting HMGCR activity.
Synapse has enriched 10 related papers. Consider them for comparative context: